XHKG
2137
Market cap187mUSD
Jul 31, Last price
2.01HKD
1D
-3.37%
1Q
-3.83%
IPO
-90.86%
Name
Brii Biosciences Ltd
Chart & Performance
P/E
—
P/S
24.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.67%
Rev. gr., 5y
21.87%
Revenues
54m
-3.61%
Net income
-508m
L+190.66%
CFO
0k
P
Earnings
Aug 18, 2025
Profile
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 54,286 -3.61% | 56,322 9.10% | 51,626 -44.21% | |||
Cost of revenue | 453,790 | 459,809 | 520,960 | |||
Unusual Expense (Income) | ||||||
NOPBT | (399,504) | (403,487) | (469,334) | |||
NOPBT Margin | ||||||
Operating Taxes | (37,155) | |||||
Tax Rate | ||||||
NOPAT | (399,504) | (403,487) | (432,179) | |||
Net income | (508,162) 190.66% | (174,829) -61.37% | (452,626) -89.01% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (983) | 6,769 | ||||
BB yield | 0.06% | -0.13% | ||||
| Debt | ||||||
Debt current | 4,896 | 3,156 | 9,500 | |||
Long-term debt | 33,173 | 3,156 | 15,812 | |||
Deferred revenue | 2,083 | |||||
Other long-term liabilities | 2,083 | |||||
Net debt | (2,303,809) | (625,782) | (1,311,288) | |||
| Cash flow | ||||||
Cash from operating activities | (594,014) | (496,279) | ||||
CAPEX | (139,292) | |||||
Cash from investing activities | (104,350) | (1,433,168) | ||||
Cash from financing activities | (10,977) | (3,042) | ||||
FCF | (415,695) | (390,989) | (418,266) | |||
| Balance | ||||||
Cash | 2,332,680 | 2,660,661 | 2,997,384 | |||
Long term investments | 9,198 | (2,028,567) | (1,660,784) | |||
Excess cash | 2,339,164 | 629,278 | 1,334,019 | |||
Stockholders' equity | 2,606,080 | (6,304,396) | (6,194,616) | |||
Invested Capital | 294,936 | 9,379,934 | 9,367,074 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 730,246 | 728,100 | 723,478 | |||
Price | 0.98 -57.02% | 2.28 -69.06% | 7.37 -77.46% | |||
Market cap | 715,641 -56.89% | 1,660,068 -68.87% | 5,332,033 -62.86% | |||
EV | (1,639,045) | 987,628 | 3,983,628 | |||
EBITDA | (399,504) | (387,813) | (452,302) | |||
EV/EBITDA | 4.10 | |||||
Interest | 494 | 851 | ||||
Interest/NOPBT | ||||||